Ozempic, Weight Loss Injections and Pregnancy: What Every Woman Should Know.
Over the last few years, medications such as Ozempic (semaglutide), Wegovy, Mounjaro (tirzepatide) and Saxenda (liraglutide) have transformed obesity treatment. Many people have achieved significant weight loss, improved blood sugar control and reduced health risks.
However, alongside their popularity has come an unexpected trend: an increase in unplanned pregnancies among women using these medications.
So what is actually happening, and should people be concerned?
The Rise of the "Ozempic Baby"
The phrase "Ozempic Baby" has become increasingly common on social media.
Despite the catchy nickname, it doesn't mean the medication increases fertility directly.
Instead, there are several reasons pregnancies may become more likely after significant weight loss.
Improved fertility
Excess body fat can interfere with hormone production and ovulation.
Losing weight often improves:
Ovulation
Menstrual regularity
Insulin sensitivity
Hormonal balance
This is particularly important for women with Polycystic Ovary Syndrome (PCOS), where even modest weight loss can dramatically improve fertility.
For many women who previously struggled to conceive, fertility may return sooner than expected.
Can Weight Loss Jabs Affect Contraception?
This is where things become particularly important.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) now advises that women taking GLP-1 medications should use effective contraception if they do not wish to become pregnant.
Mounjaro (tirzepatide)
Unlike other GLP-1 medicines, Mounjaro may reduce the effectiveness of the oral contraceptive pill, particularly during:
the first four weeks after starting treatment
four weeks after every dose increase
This happens because the medication significantly slows stomach emptying, potentially reducing absorption of oral contraceptives.
The MHRA recommends using:
a non-oral contraceptive, or
adding barrier protection (such as condoms)
during these periods.
Should You Take Ozempic During Pregnancy?
Current guidance is very clear.
No.
GLP-1 medications are not recommended during pregnancy because there is still insufficient evidence to confirm they are completely safe for a developing baby.
Animal studies have shown potential fetal harm, although this has not been clearly demonstrated in humans. Because of this uncertainty, medical professionals advise avoiding these medications while pregnant.
Planning a Pregnancy?
If you're hoping to conceive, speak with your GP or specialist before stopping your medication.
Current recommendations generally advise stopping:
Semaglutide (Ozempic/Wegovy): approximately 2 months before trying to conceive
Tirzepatide (Mounjaro): approximately 1 month before conception
This allows enough time for the medication to leave your system.
What Does the Research Say?
The good news is that recent research has become more reassuring.
Several systematic reviews published in 2025 and 2026 found that accidental exposure during early pregnancy was not associated with a statistically significant increase in major birth defects or miscarriage. However, the available evidence is still observational, and researchers stress that there is not yet enough information to recommend continuing these medicines throughout pregnancy.
The key message remains:
If you discover you're pregnant while taking one of these medications, don't panic. Contact your healthcare provider promptly for personalised advice.
Other Important Side Effects
Weight loss injections are highly effective, but they are not without risks.
Common side effects
Most people experience mild symptoms such as:
nausea
vomiting
diarrhoea
constipation
reduced appetite
indigestion
fatigue
These usually improve as the body adapts.
Loss of Muscle
Rapid weight loss doesn't only reduce body fat.
Without adequate protein intake and resistance training, people can also lose lean muscle mass.
This is one reason exercise professionals recommend combining these medications with:
strength training
sufficient dietary protein
regular physical activity
Maintaining muscle is essential for metabolism, balance, healthy ageing and long-term weight maintenance.
Gallstones
Rapid weight loss increases the risk of gallstones, whether achieved through medication or dieting.
Symptoms include:
pain beneath the right ribs
nausea
pain after fatty meals
Pancreatitis
Although uncommon, acute pancreatitis is a recognised serious adverse effect.
Seek urgent medical attention if severe upper abdominal pain develops, especially if accompanied by vomiting. The MHRA has strengthened warnings about this rare but potentially serious complication.
Eye Problems
The MHRA has also updated advice regarding a rare eye condition called non-arteritic anterior ischaemic optic neuropathy (NAION). Anyone taking semaglutide who experiences sudden vision changes should seek urgent medical assessment.
Weight Loss Is Only Part of the Journey
Weight loss injections can be incredibly effective tools, but they work best when combined with healthy lifestyle habits.
The most successful long-term results usually come from combining medication with:
resistance training
regular cardiovascular exercise
adequate protein intake
improved sleep
stress management
sustainable eating habits
Medication may help open the door, but healthy habits help keep it open.
Final Thoughts
Weight loss medications are changing the treatment of obesity, offering hope to many people who have struggled for years.
However, they're not a quick fix, and they're certainly not suitable for everyone.
If you're considering pregnancy, using contraception, or thinking about starting one of these medications, have an informed discussion with your GP, pharmacist or specialist before making any decisions.
As with any treatment, the best outcomes come when medication is combined with education, lifestyle changes and professional guidance.
References
MHRA (2025). GLP-1 medicines for weight loss and diabetes: what you need to know.
MHRA Safety Roundup (June 2025). Updated contraception guidance for GLP-1 medicines.
Varughese MS, O'Mahony F, Varadhan L. GLP-1 receptor agonist therapy and pregnancy: Evolving and emerging evidence. Clinical Medicine. 2025.
Price SAL, Nankervis A. Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: A narrative review. Archives of Gynecology and Obstetrics. 2025.
Evaluation of GLP-1 receptor agonists in obstetrics and perinatal outcomes: A systematic review and meta-analysis. Journal of Obstetrics and Gynaecology. 2025.
Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nature Reviews Drug Discovery. 2025.
